American College of Tax Counsel Urges U.S. Supreme Court to Review Retroactivity Case

Bernard Knight called the Supreme Court’s Cuozzo decision “bad for patent owners, especially for biopharmas,” because it upheld different patent dispute resolution standards for the Patent Trial and Appeal Board and the federal courts. Life sciences companies that criticized the decision “should be looking to Congress” for a remedy, Mr. Knight added.